BIONTECH SE SPON. ADRS 1
Commented by Nico Popp on February 10th, 2022 | 11:14 CET
BioNTech, Cardiol Therapeutics, Peloton: Future check on pandemic stocks
There are pandemic stocks that are already out today. But there are also pandemic stocks that are only now taking off operationally. We take a look at three stocks and do a future check: Where has the pandemic only provided the initial spark, and where is the hype irretrievably over?
Read
Commented by Stefan Feulner on February 9th, 2022 | 12:20 CET
BioNTech, Barsele Minerals, Pfizer - Markets facing a turnaround
The vaccination pace in Germany continues to decline. According to experts, the Omicron variant could be the end of the pandemic and the change to an endemic. Is this why we have already seen the highs in vaccine manufacturers? With the FED's plan to raise interest rates in several steps, technology stocks corrected sharply, while new life was breathed into shares from the financial services sector. Companies in the gold sector should also be in strong demand over the long term because one thing is certain, even if the pandemic goes away, government debt will remain.
Read
Commented by André Will-Laudien on February 3rd, 2022 | 13:55 CET
Novavax, XPhyto Therapeutics, BioNTech, Valneva - The vaccine blockbusters are on the move again!
It is on again with the vaccine producers. Experts consider the pandemic to be over by the summer of 2022, but vaccination rates are still low, and infection figures are rushing from record to record. Meanwhile, mandatory vaccination by law is also a daily topic of discussion, dividing society into at least two camps. According to the thinking of those currently taking action, the right to freedom of bodily integrity probably ceases when third parties could suffer a disadvantage as a result of one's own decision. It's so easy to knit laws under the postulate of "protection & general welfare," and the individual right to liberty under the Basic Law is thus unceremoniously nullified. After all, members of parliament are supposed to be able to vote without factional coercion. We evaluate the chances of the well-known biotech protagonists!
Read
Commented by Armin Schulz on January 31st, 2022 | 13:31 CET
BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype
The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.
Read
Commented by Stefan Feulner on January 26th, 2022 | 13:05 CET
BioNTech, Desert Gold, Nel ASA - Rebound or crash
The stock markets are shaking dangerously. After the highs at the beginning of the year, shares from the technology sector mainly corrected across the board due to rising fears of a stricter monetary policy by central banks. The fact that tensions between Russia and Western countries are escalating due to the Ukraine conflict is exacerbating the sell-off. Despite good corporate data, individual companies are being swept along in the undertow and currently offer attractive anti-cyclical entry opportunities.
Read
Commented by Nico Popp on January 25th, 2022 | 10:15 CET
BioNTech, Defence Therapeutics, Nordex: Investors must pay attention here!
"Defying cancer" was the headline of the Frankfurter Allgemeine Zeitung a few days ago. The interview was illustrated with the two leading BioNTech heads, Özlem Türeci and Uğur Şahin. The famous German scientists' statement revolved around further projects for BioNTech and the fight against cancer. At the same time, BioNTech's stock, like many other pandemic winners, dropped. What does this mean for investors now?
Read
Commented by Stefan Feulner on January 24th, 2022 | 11:09 CET
BioNTech, Cardiol Therapeutics, Netflix - The return to normality
The outbreak of the Corona pandemic triggered gold-rush sentiment among many companies. In addition to vaccine manufacturers such as BioNTech and Moderna, stocks whose technology supported the mandated measures also multiplied. Whether shopping, school, work or even sports, one could suddenly do everything simply in front of a screen. However, after the restrictions and limitations, society longs for normal life to return. These developments can be seen clearly in the share charts and the most recently presented figures.
Read
Commented by Stefan Feulner on January 20th, 2022 | 09:15 CET
Valneva, XPhyto, BioNTech - This is the breakthrough
The shares of vaccine manufacturers are currently experiencing a rollercoaster ride. While BioNTech, Pfizer and Moderna vaccines, based on mRNA technology, continue to reduce their incredible stock market valuation, Valneva, the manufacturer of an inactivated vaccine, has made a brilliant comeback on the stock market floor. The reasons for the good mood were positive data regarding the neutralization of the Omicron variant, which pushed the share up by more than 30% after trading hours.
Read
Commented by Mario Hose on January 18th, 2022 | 16:37 CET
Buy Long-Covid Stock Now? BioNTech, Cardiol, Mainz Biomed
The second trading day this week is characterized by a weak start to trading. In the first two hours, the German indices have clearly lost ground. The leading index DAX is currently trading at 15,776 points, down around 1.05% on the previous day. The MDAX last traded at 34,156 points (-1.38%), TecDAX at 3,498 points (-1.77%) and SDAX at 15,658 points with 1.65% in the red. In the focus of market participants today are repeatedly the shares of vaccine manufacturers, but the trend is now also to the next phase of the Corona situation, the treatment of Long-Covid.
Read
Commented by Mario Hose on January 17th, 2022 | 15:57 CET
Which stocks should investors buy? BioNTech, Desert Gold, Unilever in focus
The start of the week in Germany has been mixed. At 15,937 points, the German benchmark index DAX is almost unchanged from the close of trading last Friday. No impulses are expected from the U.S. today, as the stock market there remains closed for the holiday. The MDAX last traded at 34,667 points (+0.24%), TecDAX at 3,563 points (+0.53%) and SDAX at 15,872 points with 0.07% in the red. Detached from the indices, investors have special opportunities today in individual stocks.
Read